Scandinavian ChemoTech announces postponement of the quarterly report

In connection with the ongoing rights issue, the Company has decided to postpone the publication of the quarterly report for Q3. New publication date is set for November 22nd.

k Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.

For further information please contact: Mohan Frick, CEO

+46 (0)10-218 93 00

ir@chemotech.se

Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.